February 29, 2024
“Shares of Viking Therapeutics closed more than 120% higher on Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say… Continue Reading…
January 3, 2024
“Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices in the United States on more than 500 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors. The expected price hikes come as the pharmaceutical industry gears… Continue Reading…
December 11, 2023
“Drug shortages in the U.S. have hit a record high and lawmakers warn they could mean life or death for millions of patients. A House committee is investigating what Congress can do to the supply chain to make sure doctors… Continue Reading…
October 23, 2023
“Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a “promising new therapy”… Continue Reading…
August 1, 2023
“U.S. pharmacy chain CVS Health is cutting 5,000 jobs, the Wall Street Journal reported on Monday, citing a staff memo. In an emailed response to Reuters, CVS confirmed the company was laying off some non-customer facing employees to cut costs,… Continue Reading…
May 17, 2023
“Pfizer Inc. sold $31 billion of debt in the fourth-largest US bond sale ever, according to a person with knowledge of the matter. The pharmaceutical giant raked in over $85 billion in orders for the eight part investment-grade deal, which… Continue Reading…
August 12, 2022
“Shares of GlaxoSmithKline, Sanofi and Haleon all sold off sharply this week, shedding tens of billions in market value, amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac. This has been a known issue bubbling in the background for years… Continue Reading…
October 5, 2020
“Bristol-Myers Squibb said on Monday it would buy MyoKardia for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs. The deal follows Bristol-Myers’ $74 billion acquisition of Celgene last… Continue Reading…
October 1, 2020
“When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards. It was the gamble of… Continue Reading…
September 15, 2020
“Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday. Shares of Immunomedics surged more than 100% in premarket trading Monday. The deal will provide Gilead access to the drug Trodelvy, a… Continue Reading…
Recent Comments